Evidence mapPaperPMID 41758481Full record

ReviewMetabolomics : Official journal of the Metabolomic Society2026

Artificial intelligence to investigate metabolomics data for precision medicine.

Antony Shenouda, Sahana Senthilkumar, Youssef Mourad, Joy Xie, Elizabeth Peker, Saman Zeeshan, Zeeshan Ahmed

Abstract readReview
In one paragraph

Review in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antony Shenouda *Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, 112 Paterson Street, New Brunswick, NJ, 08901, USA.
Sahana Senthilkumar *Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, 112 Paterson Street, New Brunswick, NJ, 08901, USA.
Youssef Mourad *Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, 112 Paterson Street, New Brunswick, NJ, 08901, USA.
Joy Xie *Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, 112 Paterson Street, New Brunswick, NJ, 08901, USA.
Elizabeth Peker *Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, 112 Paterson Street, New Brunswick, NJ, 08901, USA.
Saman ZeeshanDepartment of Biomedical and Health Informatics, UMKC School of Medicine, 2411 Holmes Street, Kansas City, MO, 64108, USA.
Zeeshan AhmedRutgers Institute for Health, Health Care Policy and Aging Research, Rutgers, The State University of New Jersey, 112 Paterson Street, New Brunswick, NJ, 08901, USA. zahmed@ifh.rutgers.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolomic data offers insights into disease mechanisms, diagnostics, and therapeutic targets by analyzing metabolic profiles. In analyzing these profiles, traditional bioinformatic and statistical approaches, while valuable, often struggle to process high-dimensional and nonlinear metabolic data, lacking the sensitivity and adaptability that artificial intelligence (AI) and machine learning (ML) techniques provide. The integration of AI/ML has greatly enhanced the metabolomics field, enabling biomarker identification, disease prediction, and classification of metabolic patterns at an unprecedented level. AIM OF REVIEW: This study analyses and compares the scientific goals, methodologies, datasets, and sources of AI/ML approaches applied to metabolomic data, as well as assessing their implications in precision medicine. We systematically reviewed recent advancements in AI/ML applications to metabolomic data, focusing on peer-reviewed research indexed in PubMed. Significant number of studies were analyzed, covering diseases such as cancer, cardiovascular diseases, and diabetes. Our results showed that the most used AI/ML techniques were SVM, RF, Gradient Boosting, and Logistic Regression, highlighting their effectiveness in processing complex metabolic data. Despite these advancements, key challenges persist in AI/ML applications to metabolomics data, including small cohort sizes, data heterogeneity, and the need for improved model interpretability, and these challenges must be considered for future use. KEY SCIENTIFIC CONCEPTS OF REVIEW: Ultimately, our findings underscore the transformative potential of AI/ML in metabolomics and its critical role in advancing precision medicine by uncovering novel metabolic pathways, improving treatment strategies, and enabling the earlier diagnosis of diseases through predictive metabolic profiling.

Indexed as

Artificial IntelligenceMetabolomicsPrecision MedicineData AnalyticsHumansMachine LearningArtificial Intelligence, Machine LearningMetabolomicsPrecision MedicineTherapeutic

Identifiers

PMID41758481
PMCPMC12948907

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.